Stockscreener 앱 받기
3.545
2.07%
-0.075
전일 마감가:
$3.62
열려 있는:
$3.37
하루 거래량:
5,113
Relative Volume:
0.02
시가총액:
$233.57M
수익:
$7.69M
순이익/손실:
$-17.65M
주가수익비율:
-9.471
EPS:
-0.3743
순현금흐름:
$-15.72M
1주 성능:
-0.14%
1개월 성능:
-17.94%
6개월 성능:
+120.19%
1년 성능:
+122.96%
1일 변동 폭
$3.26
$3.62
1주일 범위
$3.26
$3.88
52주 변동 폭
$1.30
$4.75
에이다진 Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.535 | 239.18M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
428.60 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
718.43 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.45 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.43 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.57 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
에이다진 Stock (ADAG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Guggenheim | Buy |
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2025-01-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 개시 | China Renaissance | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
에이다진 주식(ADAG)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Adagene announces pricing of $70M public offering of ADS - MSN
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
ADAG Stock Price, Quote & Chart | ADAGENE INC-ADR (NASDAQ:ADAG) - ChartMill
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Qinghai Zhao Net Worth (2026) - GuruFocus
Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa
Adagene reports trial data for cancer drug muzastotug combos - Investing.com
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
Analysts Offer Predictions for Adagene FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm
Leerink raises Adagene stock price target to $8 on combination data - Investing.com India
[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net
Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - wahanariau.com
Adagene sets $3.75 per ADS price for $70M offering - MSN
Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer - TipRanks
Adagene prices $70 million public offering at $3.75 per ADS - Investing.com
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline - TipRanks
Adagene reports 31% response rate in colorectal cancer trial By Investing.com - Investing.com India
Adagene reports 31% response rate in colorectal cancer trial - investing.com
Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Bitget
Adagene (ADAG) launches ADS offering to fund ADG126 and pipeline - Stock Titan
Updated Data from Phase 1b/2 Study of Muzastotug in - GlobeNewswire
Adagene (ADAG) reports stronger 20 mg/kg muzastotug results and Fast Track status - Stock Titan
Why Is ADAG Stock Tanking Today? - Stocktwits
Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028 - TipRanks
Adagene (NASDAQ: ADAG) revenue jumps in 2025 as losses narrow and cash runway extends - Stock Titan
Regulatory pressure around China puts Adagene (ADAG) Nasdaq listing at risk - Stock Titan
Empowering Investor Success - Morningstar
에이다진 (ADAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
3.01%
자본화:
|
볼륨(24시간):